Stock Upgrades: Zentalis Pharmaceuticals Shows Rising Relative Strength

In a welcome move, Zentalis Pharmaceuticals (ZNTL) saw its Relative Strength Rating improve from 70 to 73 on Thursday.

As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength.

IBD's unique RS Rating identifies market leadership by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.

Over 100 years of market history shows that the stocks that go on to make the biggest gains tend to have an 80 or better RS Rating in the early stages of their moves. See if Zentalis Pharmaceuticals can continue to rebound and clear that threshold.

See How IBD Helps You Make More Money In Stocks

Zentalis Pharmaceuticals is building a consolidation with a 31.46 entry. See if it can clear the breakout price in heavy volume.

Zentalis Pharmaceuticals reported 0% earnings growth last quarter, while sales growth came in at 0%. Keep an eye out for the company's next round of numbers on or around Aug. 9.

The company earns the No. 73 rank among its peers in the Medical-Biomed/Biotech industry group. Arcturus Therapeutics (ARCT) and Kiniksa Pharmaceuticals (KNSA) are also among the group's highest-rated stocks.

Get these newsletters delivered to your inbox & more info about our products & services. Privacy Policy & Terms of Use

YOU MAY ALSO LIKE:

Biotech And Pharmaceutical Industry And Stock News

Stocks With Rising Relative Strength Ratings

Why Should You Use IBD's Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock

Find Top Stocks Near A Buy Point With IBD Leaderboard